Review paper

Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Volume: 75, Issue: 4, Pages: 435 - 447
Published: Feb 1, 2020
Abstract
Changes in the regulatory guidelines by the U.S. Food and Drug Administration and the European Medical Agency requiring large-scale trials that study the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2 diabetes mellitus. Unexpectedly, these trials demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes. This second part of this 2-part review summarizes the...
Paper Details
Title
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Published Date
Feb 1, 2020
Volume
75
Issue
4
Pages
435 - 447
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.